What Happened?
Shares of pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) jumped 4.9% in the afternoon session after the company reported third-quarter 2025 financial results that surpassed analyst expectations.
The pharmaceutical company posted revenue of $191.8 million, beating Wall Street's consensus estimate of $184.5 million. Its adjusted earnings per share of $0.93 also came in ahead of expectations of $0.83. While revenue was flat compared to the same period last year and operating margins declined, investors appeared to focus on the company's ability to outperform analyst forecasts on both the top and bottom lines.
After the initial pop the shares cooled down to $24.95, up 3% from previous close.
Is now the time to buy Amphastar Pharmaceuticals? Access our full analysis report here.
What Is The Market Telling Us
Amphastar Pharmaceuticals’s shares are somewhat volatile and have had 12 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The previous big move we wrote about was 28 days ago when the stock dropped 5.2% on the news that worries over worsening trade relations with China were triggered by critical comments from President Donald Trump. The president's tone and the suggestion of canceling a meeting with President Xi caused a rapid sell-off in the market. The trade dispute flared up after China imposed export controls on rare earth minerals, which are critical components for high-tech manufacturing. The escalation of the trade war raises concerns about supply chain disruptions and increased costs for technology companies, which are heavily reliant on global trade, leading to a broad sell-off in the sector.
Amphastar Pharmaceuticals is down 31.4% since the beginning of the year, and at $24.95 per share, it is trading 48.6% below its 52-week high of $48.57 from November 2024. Investors who bought $1,000 worth of Amphastar Pharmaceuticals’s shares 5 years ago would now be looking at an investment worth $1,312.
While Wall Street chases Nvidia at all-time highs, an under-the-radar semiconductor supplier is dominating a critical AI component these giants can’t build without. Click here to access our full research report.
